Ram Mukunda, CEO of IGC Pharma, shared his optimism about the trial's expansion, which aims to bolster data collection and diversify the patient population. IGC Pharma is on track to open additional trial sites in the U.S. and Canada to ensure a representative sample of participants, including underrepresented populations. IGC Pharma's portfolio focuses on addressing Alzheimer's disease through various therapeutic angles, including neuroinflammation, beta-amyloid plaques, and neurofibrillary tangles. POTOMAC, Md. - IGC Pharma, Inc.  NYSE American  IGC  has initiated a Phase 2b clinical trial through ClinCloud, a Florida-based clinical research facility, to evaluate the safety and efficacy of IGC-AD1, a drug aimed at treating agitation in Alzheimer s patients.
IGC Pharma has initiated a Phase 2b clinical trial to evaluate the safety and efficacy of IGC-AD1, a drug aimed at treating agitation in Alzheimer's patients. The trial will open additional sites in the U.S. and Canada to ensure a representative sample of participants, including underrepresented populations.